CCT2 Recombinant Monoclonal Antibody

CCT2, also known as T-complex protein 1 subunit beta, serves as an essential component of the chaperonin-containing TCP1 complex, a molecular machine critical for the proper folding of newly synthesized proteins in the cytosol. This chaperonin plays a particularly important role in the folding of actin, tubulin, and other cytoskeletal proteins, making it a key player in cellular architecture, division, and motility. Dysregulation of CCT2 has been implicated in various disease states, including cancer progression and neurodegenerative disorders, positioning it as a valuable target for researchers investigating protein homeostasis and cellular stress responses.

This recombinant monoclonal antibody, generated from a synthesized peptide derived from human CCT2, offers the reproducibility and sequence-defined consistency that demanding experimental workflows require. As a recombinant clone, it eliminates the lot-to-lot variability often encountered with traditional hybridoma-derived antibodies, ensuring your results remain comparable across extended studies.

Validation testing demonstrates robust performance across multiple applications. Western blot analysis confirms specific detection at the expected 57 kDa molecular weight across diverse sample types, including human cell lines such as Jurkat, Raji, HeLa, and SW620, as well as mouse and rat brain tissue lysates, confirming reliable cross-species reactivity. Flow cytometry validation using Raji cells shows clear positive signal separation from isotype controls, supporting intracellular detection applications.

Whether you are investigating chaperone-mediated protein folding, exploring CCT2's role in cytoskeletal dynamics, or examining its involvement in disease pathology, this antibody provides the flexibility to move seamlessly between western blotting and flow cytometry platforms while maintaining consistent, dependable results.